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Abstract:  HIV-1  resistance  to  3'-azido-2',3'-deoxythymidine  (AZT,  zidovudine)  results 
from mutations in reverse transcriptase that increase the ability of the enzyme to excise 
AZT-monophosphate after it has been incorporated. Crystal structures of complexes of 
wild type and mutant reverse transcriptase with double-stranded DNA with or without the 
excision product, AZT adenosine dinucleoside tetraphosphate (AZTppppA), have recently 
been  reported  [1].  The  excision-enhancing  mutations  dramatically  change  the  way  the 
enzyme interacts with the excision product.  
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In a recent paper [1], investigators at Rutgers University in Piscataway, New Jersey, The National 
Cancer  Institute  in  Frederick,  Maryland,  and  The  University  of  Missouri  in  Columbia,  Missouri, 
described  several  crystal  structures  of  HIV-1  reverse  transcriptase  (RT)  containing  resistance 
mutations  to  3'-azido-2',3'-deoxythymidine  (AZT, zidovudine)  that  provide new molecular insights 
into a major mechanism of resistance of HIV-1 to AZT, the first antiretroviral drug approved by the 
U.S. Food and Drug Administration for use in the AIDS epidemic. 
Several nucleoside analogs lacking the 3' OH have proven to be useful therapeutic agents against 
HIV  infection;  however,  prolonged  use  of  these  drugs  leads  to  selection  of  resistance  mutations. 
Resistance  to  AZT  is  not  usually  associated  with  reduced  ability  of  the  mutant  RT  to  bind  AZT 
triphosphate  (AZTTP)  or  to  incorporate  AZT  monophosphate  (AZTMP).  Instead,  the  mutant  RTs 
incorporate  AZTMP  as  efficiently  as  wild  type  RT,  but  have  increased  ability  to  excise  the  




chain-terminating residue after it has been incorporated [2,3]. Excision is accomplished by transfer of 
the AZTMP moiety to an acceptor substrate, removing the block to elongation so that the DNA chain 
is free to be elongated with natural nucleotides. Enhanced excision by these mutants is not limited to 
AZTMP and can extend to other nucleoside RT inhibitors, but resistance is typically much greater for 
AZT than for other chain terminators [4]. The mutants are widely referred to as thymidine analog 
resistance mutations (TAMs).  
Excision  occurs  through  a  mechanism  related  to  pyrophosphorolysis,  the  reversal  of  the  DNA 
polymerization  reaction.  In  pyrophosphorolysis,  the  3'-terminal  nucleotide  on  the  primer  strand  is 
transferred  to  pyrophosphate  forming  the  corresponding  nucleoside  triphosphate.  HIV-1  RT  has  a 
unique  ability  to  use  cellular  nucleoside  triphosphates  in  place  of  pyrophosphate  in  this  reaction 
forming dinucleoside tetraphosphate as the excision product [5]. The nucleoside triphosphate most 
readily available for excision in the intracellular environment is ATP, and it is considered the most 
likely candidate for acceptor substrate in the in vivo reaction. The product of ATP-dependent excision 
of  AZTMP  is  AZT  adenosine  dinucleoside  tetraphosphate  (AZTppppA)  and  the  formation  of 
AZTppppA is enhanced in in vitro reactions with mutant RTs containing TAMs [3]. The new crystal 
structures reported by Tu et al. [1] provide direct structural evidence to explain enhanced excision  
by the mutant RTs. 
These  authors  have  described  ternary  complex  crystal  structures  consisting  of  wild  type  or  
AZT-resistant  mutant  RT,  27:21-mer  double-stranded  DNA,  and  AZTppppA,  using  a  previously 
reported cross-linking strategy [6,7]. Cross-linking was introduced between a cysteine introduced by a 
Q258C mutation in the large subunit of RT (p66 subunit) and an N
2-thioalkyl tether attached to an 
internal G in the primer strand. The investigators also introduced dideoxy-AMP at the 3' terminus of 
the primer strand to prevent reincorporation of AZTMP. The primer-template contains a template dA 
in the polymerase active site allowing it to base-pair with an incoming T analog. AZTppppA was 
prepared synthetically and bound in the dNTP-binding site on the enzyme to form a stable closed 
ternary complex. The mutant RT contained five of the most prevalent TAMs (M41L, D67N, K70R, 
T215Y and K219Q). Structures were obtained for ternary complexes with wild type RT and mutant RT 
at resolutions of 3.15 Å and 3.2 Å, respectively. The investigators also determined structures for two 
binary complexes containing the mutant enzyme in complex with AZTMP-terminated dsDNA and a 
structure for the unliganded mutant RT. 
The most remarkable finding from these structures is that the AMP portion of AZTppppA occupies 
very different positions in wild type and mutant RT (Figure 1). The AMP binding site is well defined 
in the mutant complex, but much more variable in the wild type complex. In both of these complexes 
AZTppppA is recognized as an analog of TTP and the AZTTP portion of the molecule superimposes 
closely with TTP in the ternary complex containing wild type RT, dsDNA and TTP [8]. The AMP 
portion of AZTppppA finds a place to bind near site I in wild type RT (Figure 1), but does not form 
distinctive interactions with RT residues. By contrast, the primary TAMs (T215Y and K70R), form a 
new binding site for AMP on the surface of the enzyme that causes the AMP moiety to bind more 
tightly at an alternative position (site II), about 10 Å from the binding site in the wild type enzyme. 
AZTppppA binding to both mutant and wild type enzyme is dominated by the interaction with the 
AZTTP portion of the molecule, which is not much affected by the TAMs. These results are consistent 




TTP and AZTTP, and that AZTppppA is a good substrate for AZTMP incorporation by the mutant 
enzyme (in fact it is a better substrate than AZTTP [9]), but a poor substrate for wild type RT.  
Figure 1. Comparison of binding positions of the AMP portion of AZTppppA in ternary 
complexes formed by wild type RT (Site I) and the AZT-resistant mutant RT (Site II). The 
molecular surface is shown for the AZT-resistant enzyme and the positions of the primary 
TAMs (arginine-70 and tyrosine-215). AMP carbons in the wild type complex are shown 
in grey and in the mutant enzyme complex are shown in yellow. The positions of the two 
AMPs are ~ 10 Å apart. Reprinted with permission from [1]. 
 
 
The contributions of the primary TAMs to ATP-dependent excision agree with predictions made 
previously  on  the  basis  of  molecular  modeling  [10,11].  The  adenine  ring  of  the  AMP  portion  of 
AZTppppA  interacts  with  tyrosine  215  through  a    stacking  interaction,  and  the  ribose  and   
phosphate  portions  of  AMP  interact  with  arginine  70  through  hydrogen  bonding  between  the 
guanidinium of arginine, the 3' and 5' oxygen atoms in the ribose ring, and the  phosphate. These 
observations establish a new binding site for AMP in the mutant enzyme that does not exist in the wild 
type enzyme. Secondary TAMs are mutations that confer little resistance by themselves but increase 
the level of resistance when present together with primary TAMs. The secondary TAMs, D67N and 
K219Q, can be largely understood as enhancing the ability of the AMP structure to occupy site II. 
Glutamine-219 in the mutant enzyme interacts with the 4' oxygen in the ribose ring of AMP when it 
occupies site II but, perhaps more importantly, wild type lysine at position 219 forms an ion pair with 
aspartate at position 67 [10] that could affect the access to site II. Mutation to a neutral residue at 
either position 219 or 67 would prevent the formation of the salt bridge and increase access to this site. 
Loss of interaction between residues 219 and 67 also removes a constraint on the position of the 3-4 
loop in the fingers portion of the enzyme (residue 67 is at the tip of that loop). Excision is known to  
be  enhanced  by other mutations that alter the  3-loop including dipeptide insertions following 




The contribution of the M41L mutation is still something of a mystery although it is arguably the 
most  important  secondary  TAM  based  on  the  high  frequency  with  which  the  M41L/T215Y 
combination is observed [16]. This residue is not close enough for direct interaction with any portion 
of the AZTppppA ligand in the mutant RT ternary complex structure; however, in infected cells, the 
M41L mutation substantially enhances AZT resistance when the T215Y mutation is also present. The 
leucine at position 41 is 3.9 Å from phenylalanine-116 and the authors speculate that this interaction 
may stabilize binding between the 3'-azido group at the primer terminus and the binding pocket formed 
by alanine-114, tyrosine-115, phenylalanine-116 and glutamine-151, which would favor binding of the 
primer  terminus  in  the  dNTP  binding  site  (N-site).  Preferential  N-site  occupancy  by  the  mutant 
enzyme could help explain enhanced excision activity since the primer terminus must be located in the 
N-site for excision to occur.  
Tu et al. [1] also report structures of binary complexes in which the primer-terminating AZTMP 
occupies the pre-translocation (N-site) or post-translocation (P-site) positions on the mutant RT. In the 
P-site complex, the p66 fingers subdomain residues occur in an ―open‖ configuration as they do in 
other  binary  complex  structures  including  the  wild  type  N-site  and  P-site  complexes  previously 
published  by  these  investigators  [17].  By  contrast,  the  fingers  subdomain  occurs  in  a  ―closed‖ 
configuration in the mutant N-site complex giving it an overall structure that is similar to the ternary 
complexes containing the excision product. The authors suggest that the closed structure may depend 
on the presence of a primer-terminal AZTMP in the N-site. AZTMP-terminated primer-templates have 
previously  been  shown  to  bind  preferentially  in  the  pre-translocation  position  on  the  wild  type 
enzyme [18,19]. The authors point out that the availability of a closed N-site binary complex and a 
closed ternary complex containing AZTppppA provides a unique opportunity to model the transition 
state  in  the  excision  reaction.  The  resulting  model  suggests  that  the  transition  state  intermediate 
matches the intermediate formed during DNA polymerization. The attacking  phosphate of the ATP 
excision substrate is positioned ~ 3 Å from the  phosphate of the primer terminal AZTMP and the 
attacking    phosphate  oxygen  assumes  an  almost  collinear  position  with  respect  to  the  scissile 
phosphate bond of AZTMP prior to the attack.  
In summary, our previous understanding of the mechanism of AZT resistance was based largely on 
molecular  modeling  using  the  ternary  complex  containing  WT  RT,  dsDNA  and  the  incoming 
dNTP [8]. The new structures confirm many of the conclusions from that modeling; however, they 
have also provided some surprises. A new binding site for the AMP moiety is formed in the mutant 
enzyme that was not present in the wild type enzyme, and the pre-excision binary complex of mutant 
RT  and  AZTMP-terminated  primer-template  occurs  in  a  ―closed‖  configuration.  Some  questions 
remain:  Notably,  why  does  the  selection  of  TAMs  divide  into  two  different  pathways—the  more 
common  TAM-1  pathway  (leading  to  M41L,  L210W  and  T215Y)  and  the  less  common  TAM-2 
pathway (leading to D67N, K70R, T215F and K219Q/E) [20]? And why are the K70R and M41L 
mutations  antagonistic  to  each  other  during  the  early  stages  of  selection  [21]?  Nonetheless,  the 
availability of these new structures provides an invaluable resource for the design of drugs that target 
the resistant enzyme. These results may lead to the development of drugs that increase the potency of a 
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